First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris - KEYC - Mankato News, Weather, Sports -

First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris

  • Friday, May 24 2013 11:50 PM EDT2013-05-25 03:50:56 GMT
    Kim Hunt had melanoma four years ago. She says sunscreen was not a priority when she was younger. "I wouldn't reapply all the time because although I knew that I wasn't really going to get tan. There
    The agency hopes new labels will make it easier for consumers to choose the best products to protect against the sun.

  • Friday, May 24 2013 10:34 PM EDT2013-05-25 02:34:53 GMT
    They didn't just have to use the Force, but a lot of force to get a new LEGO creation to Times Square. The LEGO Group unveiled the world's largest model ever assembled of the bricks this morning in the
    They didn't just have to use the Force, but a lot of force to get a new LEGO creation to Times Square. The LEGO Group unveiled the world's largest model ever assembled of the bricks this morning in the

  • Friday, May 24 2013 8:35 PM EDT2013-05-25 00:35:59 GMT
    Emergency responders converge on 1107 Warren Street in Mankato after a pedestrian is hit by a pickup truck. The call came in after 4:00 today. Officials say a woman was taken to the hospital. The extent
    Just after 4:00 p.m. a woman was hit by a pickup truck. Officials say her condition at the hospital is unknown at this time.
    •   

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.

SOURCE Tris Pharma

MONMOUTH JUNCTION, N.J., March 11, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01.

Under the collaboration, POC required the successful completion of several activities, including a successful human pilot comparative study against an immediate release reference product. Assuming continued clinical success, Tris expects to file a New Drug Application with the U.S. Food & Drug Administration for CCP-01 in mid-2014.

"We're very pleased to have achieved proof-of-concept for CCP-01," said Ketan Mehta, President and CEO of Tris Pharma. "Our propriety OralXR+™ technology is ideally suited to bring long-lasting relief to U.S. cough and cold sufferers, which our research has identified as a significant unmet need."

Ian Garland, CEO of Vernalis, commented, "We are delighted with this early success in our collaboration with Tris and look forward to a productive 2013 when we anticipate further significant progress for our cough/cold pipeline."

Under the deal announced in February 2012, Vernalis is paying Tris to develop up to six unique OralXR+ based extended-release liquid equivalents to existing immediate release prescription cough/cold treatments. The companies have not disclosed the financial terms of their collaboration.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.

 

©2012 PR Newswire. All Rights Reserved.